2018 Whitepapers and Content

While globalisation has opened the doors for companies to expand their businesses across borders into new markets, these growth opportunities come with certain challenges.

The U.S. pharmaceutical and biomedical sectors are experiencing a period of tumultuous mergers and acquisitions (M&A) as companies face pressures from financial investors to increase growth, and a changing healthcare system is shaping new business models. But many mergers often fail, largely because of sharp cultural differences in the merged companies.

An M&A must be well planned if its full value is to be achieved. Extensive research and experience have shown that effective integration requires top leadership to drive the transformation. A common vision and good plan are essential, communication with all stakeholders is a must, and cultural differences must be understood and managed.

With the extensive M&A activity breaking apart and recreating pharmaceutical and biomedical companies, we are seeing the future pharmaceutical company emerge.

In the current economic climate, Pharma companies are under growing pressure: companies have lost billions of dollars in annual revenue due to patents coming to an end, and have seen their market share eroded by cheaper generic drugs. As a result, some procurement organisations are facing severe